Effect of CX3CL1/CX3CR1 gene polymorphisms on the clinical efficacy of carboplatin therapy in Han patients with ovarian cancer
Gene polymorphisms have a close relationship with the clinical effects of carboplatin for ovarian cancer. Here, we investigated the relationship between CX3CL1 and CX3CR1 genotypes and the clinical efficacy of carboplatin in ovarian cancer, thereby clarifying the unidentified genetic factors that in...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2022.1065213/full |
| _version_ | 1797959951754199040 |
|---|---|
| author | Xin-Chen Wang Hong Zhou Wen-Jing Jiang Peng Jiang Yan-Cai Sun Wei-Jian Ni Wei-Jian Ni |
| author_facet | Xin-Chen Wang Hong Zhou Wen-Jing Jiang Peng Jiang Yan-Cai Sun Wei-Jian Ni Wei-Jian Ni |
| author_sort | Xin-Chen Wang |
| collection | DOAJ |
| description | Gene polymorphisms have a close relationship with the clinical effects of carboplatin for ovarian cancer. Here, we investigated the relationship between CX3CL1 and CX3CR1 genotypes and the clinical efficacy of carboplatin in ovarian cancer, thereby clarifying the unidentified genetic factors that influence the efficacy of carboplatin in ovarian cancer. Based on the above purposes, we used Sequenom Mass ARRAY technology to detect CX3CL1 and CX3CR1 gene polymorphisms in 127 patients with carboplatin-treated ovarian cancer. We performed various statistical analyses to evaluate the effects of CX3CL1 and CX3CR1 genetic variants, demographic data, and clinical characteristics on the effect of carboplatin therapy. The results show that the CX3CL1 genotypes rs223815 (G>C) and rs682082 (G>A) will significantly affect the clinical efficacy of carboplatin for ovarian cancer (p < 0.05), while the other six genotypes and all CX3CR1 genotypes have no significant effect (p > 0.05). In addition, only one population factor, age, had a significant effect on the clinical efficacy of carboplatin-treated ovarian cancer (p < 0.05). Based on the above research results, we concluded that the clinical efficacy of carboplatin in ovarian cancer patients was significantly correlated with age and CX3CL1 polymorphism factors; however, more in-depth effects and mechanisms need to be explored by large-scale, multicenter studies. |
| first_indexed | 2024-04-11T00:38:52Z |
| format | Article |
| id | doaj.art-1cc213b848b74d0799970e365b0ddbde |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-04-11T00:38:52Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-1cc213b848b74d0799970e365b0ddbde2023-01-06T11:22:39ZengFrontiers Media S.A.Frontiers in Genetics1664-80212023-01-011310.3389/fgene.2022.10652131065213Effect of CX3CL1/CX3CR1 gene polymorphisms on the clinical efficacy of carboplatin therapy in Han patients with ovarian cancerXin-Chen Wang0Hong Zhou1Wen-Jing Jiang2Peng Jiang3Yan-Cai Sun4Wei-Jian Ni5Wei-Jian Ni6Department of Pharmacy, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Pharmacy, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Gynecological Oncology, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Pharmacy, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Pharmacy, Anhui Provincial Cancer Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaDepartment of Pharmacy, Anhui Provincial Hospital, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, ChinaInflammation and Immune Mediated Diseases Laboratory of Anhui Province, the Key Laboratory of Anti-inflammatory of Immune Medicines, Ministry of Education, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, Anhui, ChinaGene polymorphisms have a close relationship with the clinical effects of carboplatin for ovarian cancer. Here, we investigated the relationship between CX3CL1 and CX3CR1 genotypes and the clinical efficacy of carboplatin in ovarian cancer, thereby clarifying the unidentified genetic factors that influence the efficacy of carboplatin in ovarian cancer. Based on the above purposes, we used Sequenom Mass ARRAY technology to detect CX3CL1 and CX3CR1 gene polymorphisms in 127 patients with carboplatin-treated ovarian cancer. We performed various statistical analyses to evaluate the effects of CX3CL1 and CX3CR1 genetic variants, demographic data, and clinical characteristics on the effect of carboplatin therapy. The results show that the CX3CL1 genotypes rs223815 (G>C) and rs682082 (G>A) will significantly affect the clinical efficacy of carboplatin for ovarian cancer (p < 0.05), while the other six genotypes and all CX3CR1 genotypes have no significant effect (p > 0.05). In addition, only one population factor, age, had a significant effect on the clinical efficacy of carboplatin-treated ovarian cancer (p < 0.05). Based on the above research results, we concluded that the clinical efficacy of carboplatin in ovarian cancer patients was significantly correlated with age and CX3CL1 polymorphism factors; however, more in-depth effects and mechanisms need to be explored by large-scale, multicenter studies.https://www.frontiersin.org/articles/10.3389/fgene.2022.1065213/fullovarian cancerCX3CL1CX3CR1gene polymorphismcarboplatin |
| spellingShingle | Xin-Chen Wang Hong Zhou Wen-Jing Jiang Peng Jiang Yan-Cai Sun Wei-Jian Ni Wei-Jian Ni Effect of CX3CL1/CX3CR1 gene polymorphisms on the clinical efficacy of carboplatin therapy in Han patients with ovarian cancer Frontiers in Genetics ovarian cancer CX3CL1 CX3CR1 gene polymorphism carboplatin |
| title | Effect of CX3CL1/CX3CR1 gene polymorphisms on the clinical efficacy of carboplatin therapy in Han patients with ovarian cancer |
| title_full | Effect of CX3CL1/CX3CR1 gene polymorphisms on the clinical efficacy of carboplatin therapy in Han patients with ovarian cancer |
| title_fullStr | Effect of CX3CL1/CX3CR1 gene polymorphisms on the clinical efficacy of carboplatin therapy in Han patients with ovarian cancer |
| title_full_unstemmed | Effect of CX3CL1/CX3CR1 gene polymorphisms on the clinical efficacy of carboplatin therapy in Han patients with ovarian cancer |
| title_short | Effect of CX3CL1/CX3CR1 gene polymorphisms on the clinical efficacy of carboplatin therapy in Han patients with ovarian cancer |
| title_sort | effect of cx3cl1 cx3cr1 gene polymorphisms on the clinical efficacy of carboplatin therapy in han patients with ovarian cancer |
| topic | ovarian cancer CX3CL1 CX3CR1 gene polymorphism carboplatin |
| url | https://www.frontiersin.org/articles/10.3389/fgene.2022.1065213/full |
| work_keys_str_mv | AT xinchenwang effectofcx3cl1cx3cr1genepolymorphismsontheclinicalefficacyofcarboplatintherapyinhanpatientswithovariancancer AT hongzhou effectofcx3cl1cx3cr1genepolymorphismsontheclinicalefficacyofcarboplatintherapyinhanpatientswithovariancancer AT wenjingjiang effectofcx3cl1cx3cr1genepolymorphismsontheclinicalefficacyofcarboplatintherapyinhanpatientswithovariancancer AT pengjiang effectofcx3cl1cx3cr1genepolymorphismsontheclinicalefficacyofcarboplatintherapyinhanpatientswithovariancancer AT yancaisun effectofcx3cl1cx3cr1genepolymorphismsontheclinicalefficacyofcarboplatintherapyinhanpatientswithovariancancer AT weijianni effectofcx3cl1cx3cr1genepolymorphismsontheclinicalefficacyofcarboplatintherapyinhanpatientswithovariancancer AT weijianni effectofcx3cl1cx3cr1genepolymorphismsontheclinicalefficacyofcarboplatintherapyinhanpatientswithovariancancer |